VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-01

Study Completion Date

2018-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the effectiveness of cellular dermal replacement tissue vs. non-viable extracellular matrix (ECM) for the treatment of non-healing diabetic foot ulcers. Our hypothesis is that these devices are of equal efficacy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

NCT06437028

Diabetic Foot Ulcer

RECRUITING NA

Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

NCT03398538

Diabetic Foot Ulcer Ulcer Foot Diabetic Foot

COMPLETED NA

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

NCT06826339

Venous Leg Ulcer Venous Leg Diabetic Foot +6 more

RECRUITING PHASE4

Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers

NCT01181440

Diabetic Foot Ulcer

COMPLETED PHASE3

Efficacy and Safety Study of Dermal-Living Skin Replacement to Treat Diabetic Foot Ulcers

NCT00368693

Diabetic Foot Ulcer

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of care

debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape

Group Type ACTIVE_COMPARATOR

SECONDARY dressing gauze and tape

Intervention Type DEVICE

SECONDARY dressing gauze and tape

debridement, irrigation

Intervention Type PROCEDURE

debridement, irrigation

Dermagraft

debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape

Group Type EXPERIMENTAL

SECONDARY dressing gauze and tape

Intervention Type DEVICE

SECONDARY dressing gauze and tape

debridement, irrigation

Intervention Type PROCEDURE

debridement, irrigation

Dermagraft

Intervention Type DEVICE

Dermagraft per company protocol

Oasis

debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape

Group Type EXPERIMENTAL

SECONDARY dressing gauze and tape

Intervention Type DEVICE

SECONDARY dressing gauze and tape

debridement, irrigation

Intervention Type PROCEDURE

debridement, irrigation

Oasis

Intervention Type DEVICE

Oasis per company protocol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SECONDARY dressing gauze and tape

Intervention Type DEVICE

debridement, irrigation

Intervention Type PROCEDURE

Dermagraft

Dermagraft per company protocol

Intervention Type DEVICE

Oasis

Oasis per company protocol

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

(Answering NO will exclude patient):

* An Institutional Review Board (IRB) Informed Consent Form signed and dated prior to any study-related activities.
* The area of the study ulcer after debridement is between 1 cm2 and 25 cm2 at Visit 3/Week 0.
* Subjects between 18 and 85 years of age.
* Subject's highest Ankle-Brachial Pressure Index (ABPI) / Ankle-Arm Index (AAI) is greater than or equal to 0.80 and lower than 1.4 (the highest ABPI/AAI value from three measurements within last 6 months shall apply).or a toe-arm index is equal to or higher than 0.6.
* The patient has one or more diabetic ulcers on the target foot with only one ulcer selected as the study (target) ulcer. The target ulcer must be at least 4 cm from a non-target ulcer and in the Investigator's opinion, be unlikely to coalesce with another ulcer within 12 weeks of randomization.
* Subject's study ulcer is full thickness and does not extend to bone, muscle, or tendon.
* Subject's study ulcer has been present at least 4 weeks prior to the initial screening (Visit 1) or 6 weeks at randomization (Visit 3).
* Subject has been diagnosed with Type 1 or Type 2 diabetes and HbA1c is less than 10%.
* Study ulcer has no clinical feature of infection (2 signs of inflammation and elevated bacterial load of the wound).
* For female subjects of childbearing age potential, the subject has a negative pregnancy test and is not lactating for the duration of the study.
* Subject understands the requirements of this study and is willing to comply with all the study requirements.

Exclusion Criteria

(Answering YES will exclude patient):

* The subject is diagnosed with cancer and is undergoing treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before enrollment.
* The subject is diagnosed with HIV/AIDS.
* The subject is diagnosed with any bleeding disorders.
* The subject is diagnosed with any connective tissue diseases.
* For female subjects, the subject is pregnant or lactating.
* The subject has a history of illicit drug use within one year of enrollment.
* In the past year, the subject experiences episodes of drinking more than 5 alcoholic beverages in less than two hours and/or drinking alcohol has become a problem in interpersonal relationships, work, driving and/or their behavior in general.
* The subject has any active infected wounds or osteomyelitis (confirmed by bone biopsy, MRI or bone scan).
* Doppler exam within the last 365 days demonstrating reflux greater than 0.5 seconds.
* The subject is diagnosed with active Charcot as described by Saunder's classification system.
* The subject manifests signs of poor nutritional status and/or albumin level \< 2.9.
* The subject has been exposed to Dermagraft and/or Oasis in the last 60 days.
* The study ulcer size is less than 0.5 cm2 or greater than 25 cm2.
* The subject has any porcine allergy or cow product allergy.
* The subject's recent (last 30 days) chemistry tests serum creatinine is 2 times above the upper limit of normal and/or LFT's 3 times above the upper limit of normal.
* Between Visit 1/Week -2 and Visit 3/Week 0 (randomization) the study ulcer has decreased in size by more than 40%, or increased in size by more than 50%.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No